FDA’s Rx Acetaminophen Safety Program Ramps Up Enforcement
This article was originally published in The Pink Sheet Daily
Executive Summary
Some manufacturers have not met a deadline FDA set three years ago to limit the amount of acetaminophen in prescription combination products to no more than 325 mg.
You may also be interested in...
FDA Restrictions On Rx Acetaminophen Show How Practical Concerns Influence Safety Actions
Because the agency can move faster on Rx products than OTCs, non-prescription products will have higher acetaminophen levels than Rx drugs, at least for the time being.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.